Myeloproliferative Neoplasms

Management of Patients With Myelofibrosis Experiencing Ruxolitinib Failure

By

Susan Moench, PhD, PA-C

Publish Date April 3, 2020

Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.

Persistent Leukocytosis as a Marker for Disease Progression in Polycythemia Vera

By

Susan Moench, PhD, PA-C

Publish Date April 1, 2020

Although most notably associated with erythrocytosis, hematologic manifestations of polycythemia vera may also include leukocytosis and thrombocytosis.

Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms

By

Jonathan Goodman, MPhil

Publish Date March 26, 2020

Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.

Pregnancy in Myeloproliferative Neoplasms: Aspirin May Raise Likelihood of Live Birth

By

Jonathan Goodman, MPhil

Publish Date March 16, 2020

Researchers examined pregnancy outcomes in 102 patients with essential thrombocythemia.

Increased Risk of Venous Thromboembolism in Patients With Myelofibrosis

By

Susan Moench, PhD, PA-C

Publish Date March 13, 2020

One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.